World's Best Scientists 2026 revealed!
Paul J. Kurtin

Paul J. Kurtin

D-Index & Metrics

Medicine

D-Index
89
Citations
25169
World Ranking
12815
National Ranking
6549

Paul J. Kurtin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Paul J. Kurtin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 287 publications — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Paul J. Kurtin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Paul J. Kurtin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Paul J. Kurtin is affiliated with the Mayo Clinic in the United States and has a research focus primarily in medicine and biochemistry, genetics, and molecular biology. Their body of work spans key subfields such as molecular biology, pathology and forensic medicine, genetics, oncology, and nephrology.

The scientist's research extensively covers clinical and molecular aspects of amyloidosis and lymphoma diagnosis and treatment. Their main topics of study include:

  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Lymphoma Diagnosis and Treatment
  • Parathyroid Disorders and Treatments
  • Peptidase Inhibition and Analysis
  • Cancer-related Gene Regulation
  • Neuroendocrine Tumor Research Advances
  • Dermatological and Skeletal Disorders

Recent notable publications include:

  • "Systemic amyloidosis from A (AA) to T (ATTR): a review" (2020, Journal of Internal Medicine)
  • "Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples" (2020, Mayo Clinic Proceedings)
  • "Association between spinal stenosis and wild-type ATTR amyloidosis" (2021, Amyloid)
  • "Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma" (2020, The American Journal of Surgical Pathology)
  • "High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?" (2020, Blood Cancer Journal)

Frequent co-authors in their scholarly work are:

  • Ellen D. McPhail
  • Surendra Dasari
  • Jason D. Theis
  • Karen L. Rech
  • Angela Dispenzieri

The venues where Kurtin has most regularly published include:

  • Amyloid
  • Human Pathology
  • The American Journal of Surgical Pathology
  • Blood Cancer Journal
  • Journal of Internal Medicine

This profile reflects a focused expertise in the clinical and molecular pathology related to amyloidosis and lymphoma, supported by a consistent pattern of contributions in relevant peer-reviewed journals and collaborations with other researchers in adjacent fields.

Best Publications

  • Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

    Robert A. Kyle;Ellen D. Remstein;Terry M. Therneau;Angela Dispenzieri

  • The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

    Kerry J. Savage;Stefano Monti;Jeffery L. Kutok;Giorgio Cattoretti

  • Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

    Stefano Monti;Kerry J. Savage;Jeffery L. Kutok;Friedrich Feuerhake

  • Lymphoid Neogenesis in Rheumatoid Synovitis

    Seisuke Takemura;Andrea Braun;Cynthia Crowson;Paul J. Kurtin

  • Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

    Thomas E. Witzig;Susan M. Geyer;Irene Ghobrial;David J. Inwards

  • Epithelial membrane antigen--a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies.

    Geraldine S. Pinkus;Paul J. Kurtin

  • The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.

    Janet E. Olson;Carol A. Janney;Ravi D. Rao;James R. Cerhan

  • Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

    Matthew J. Maurer;Hervé Ghesquières;Hervé Ghesquières;Jean Philippe Jais;Thomas E. Witzig

  • Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.

    Jane N. Winter;Edie A. Weller;Sandra J. Horning;Maryla Krajewska

  • BLyS and APRIL in rheumatoid arthritis

    Thorsten M. Seyler;Yong W. Park;Yong W. Park;Seisuke Takemura;Richard J. Bram

  • NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes

    Friedrich Feuerhake;Jeffery L. Kutok;Stefano Monti;Wen Chen

  • Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas.

    Ellen D. Remstein;C. David James;Paul J. Kurtin

  • Leukocyte common antigen—a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: Correlation with immunologic studies and ultrastructural localization

    Paul J. Kurtin;Geraldine S. Pinkus

  • Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas

    Andrew L. Feldman;Mark Law;Ellen D. Remstein;William R. Macon

  • Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas.

    William R. Macon;Norman B. Levy;Paul J. Kurtin;Kevin E. Salhany

  • Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type.

    Paul Kurtin;Jeffrey Myers;Hakiran Adlakha;John Strickler

  • The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.

    Ellen D. Remstein;Ahmet Dogan;Richard R. Einerson;Sarah F. Paternoster

  • Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects.

    Suhail Ahmad;H. Thomas Robertson;Thomas A. Golper;Marsha Wolfson

  • Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the north central cancer treatment group

    Thomas E. Witzig;Allen M. Vukov;Thomas M. Habermann;Susan Geyer

  • Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.

    Stephen M. Ansell;David J. Inwards;Kendrith M. Rowland;Patrick J. Flynn

Frequent Co-Authors

Thomas E. Witzig
Thomas E. Witzig Mayo Clinic
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center
Surendra Dasari
Surendra Dasari Mayo Clinic
David J. Inwards
David J. Inwards Mayo Clinic
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
Samih H. Nasr
Samih H. Nasr Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring ways to enter or advance in the medical field, there are a variety of flexible online degree programs and career pathways worth considering. For instance, students interested in administrative roles might look at the medical billing and coding financial aid options available, which help make these programs more accessible and affordable.

Nursing is another popular path, and you may wonder: do you have to take the teas test to get into nursing school? Some accredited nursing schools offer admission without the typical standardized entrance exams, removing barriers for aspiring nurses.

For those aiming for leadership roles, an accelerated healthcare administration degree can quickly prepare you for managerial careers in hospitals, clinics, and beyond.

Registered nurses aiming to become nurse practitioners can consider structured adn to np bridge programs available online, which fast-track career progression without sacrificing work experience.

Each of these options provides a unique route into the healthcare industry, offering flexibility, financial support, and opportunities for advancement.

Best Scientists Citing Paul J. Kurtin

Trending Scientists